NEW YORK, May 10, 2017 /PRNewswire/ --
The iShares Nasdaq Biotechnology ETF, the largest biotechnology exchange traded
Shares in Waltham, Massachusetts headquartered Bioverativ Inc. rose 0.74%, ending Tuesday's trading session at $55.95. The stock recorded a trading volume of 823,798 shares. The Company's shares have surged 25.90% over the last three months and 24.39% on an YTD basis. The stock is trading 3.32% and 7.53% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Bioverativ, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have a Relative Strength Index (RSI) of 48.72.
On April 24th, 2017, research firm Gabelli & Co. downgraded the Company's stock rating from 'Buy' to 'Hold'.
On May 03rd, 2017, Bioverativ reported financial results for Q1 2017. Key financial results included Q1 2017 revenues of $259.1 million, GAAP net income of $69.3 million; non-GAAP net income of $74.0 million; GAAP earnings per share (EPS) of $0.64; non-GAAP EPS of $0.68; and net cash flows from operations of $108.2 million. Visit us today and download your complete report on BIVV for free at: http://stock-callers.com/registration/?symbol=BIVV
Fremont, California headquartered Zosano Pharma Corp.'s stock declined 2.56%, closing the day at $1.45 with a total trading volume of 774,997 shares. The Company's shares have advanced 22.88% in the previous three months and 85.90% since the start of this year. The stock is trading 17.42% above its 200-day moving average. Additionally, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients, have an RSI of 33.81. The complimentary research report on ZSAN can be accessed at: http://stock-callers.com/registration/?symbol=ZSAN
On Tuesday, shares in Valencia, California-based MannKind Corp. recorded a trading volume of 9.21 million shares, which was above their three months average volume of 2.51 million shares. The stock ended the day 10.89% higher at $1.12. The Company's shares have advanced 118.20% in the previous three months and 75.91% on an YTD basis. The stock is trading above its 200-day moving average by 32.17%. Furthermore, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the US, have an RSI of 50.39.
On May 04th, 2017, MannKind and One Drop announced that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend the latter's subscription service and digital health platform, which currently provides unlimited blood glucose testing supplies and 24/7 live in-app support from diabetes experts by adding Afrezza as a rapid-acting insulin offering. Register for free on Stock-Callers.com and download the PDF research report on MNKD at: http://stock-callers.com/registration/?symbol=MNKD
Palo Alto, California headquartered Ocera Therapeutics Inc.'s stock jumped 4.92%, finishing yesterday's session at $1.28 with a total trading volume of 570,655 shares. The Company's shares have advanced 4.07% in the last one month and 132.73%% in the previous three months. The stock is trading above its 50-day moving average by 6.04%. Additionally, shares of Ocera Therapeutics, which operates as a clinical stage biopharmaceutical company, have an RSI of 50.00. Get free access to your research report on OCRX at: http://stock-callers.com/registration/?symbol=OCRX
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All